TipRanksStock Market NewsAXSM NewsSVB Securities Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

SVB Securities Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

In a report issued on July 11, Marc Goodman from SVB Securities maintained a Buy rating on Axsome Therapeutics (AXSMResearch Report), with a price target of $50.00. The company’s shares closed last Thursday at $42.62.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 1.1% and a 47.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $66.60, a 49.6% upside from current levels. In a report issued on June 27, Mizuho Securities also maintained a Buy rating on the stock with a $49.00 price target.

See the top stocks recommended by analysts >>

Axsome Therapeutics’ market cap is currently $1.73B and has a P/E ratio of -11.46.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More